Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Luke Nauth

Goodwin Procter

main

Nauth Luke

Luke Nauth is an associate in Goodwin’s Technology and Life Sciences groups based in London.

Luke Nauth

Areas of Practice

Professional Activities

Credentials

Education

Legal Practice Course2017

Graduate Diploma in Law2016

MPharmMaster of Pharmacy2013

Admissions

Bars

Related Content

The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years

The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years

UK’s Medicines Regulator Announces Guidance on the New International Recognition Procedure for the Approval of New Medicines from 1 January 2024

The European Commission Proposes First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years: Orphan Medicines

The European Commission Proposes First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years: Orphan Medicines

The European Commission Proposes First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years: Regulatory Data Protection

The European Commission Proposes First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years: Regulatory Data Protection

The MHRA Proposes to Extend the Period of Acceptance of CE Marked Medical Devices in Great Britain Beyond 30 June 2023

Goodwin Advises ProQR on $69.8 Million Underwritten Public Offering Closing and $12.3 Million Concurrent Private Placement

Goodwin Advises Septerna in $288 Million Upsized Initial Public Offering

Goodwin Advises Upstream Bio on $293 Million Upsized Initial Public Offering

Goodwin Advises MBX Biosciences in Upsized Initial Public Offering

Deciphera Pharmaceuticals Completes Its Sale to ONO Pharmaceutical For $2.4 Billion

Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion

Pathos AI to Acquire Rain Oncology in All Cash Transaction Plus Contingent

Graphite Bio and LENZ Therapeutics To Merge

Technology

Life Sciences